The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Open accessAbstract
Traditional treatments for type 1 and type 2 diabetes are often associated with side effects, including weight gain and hypoglycaemia that may offset the benefits of blood glucose lowering. The kidneys filter and reabsorb large amounts of glucose, and urine is almost free of glucose in normoglycaemia. The sodium-dependent glucose transporter (SGLT)-2 in the early proximal tubule reabsorbs the majority of filtered glucose. Remaining glucose is reabsorbed by SGLT1 in the late proximal tubule. Diabetes enhances renal glucose reabsorption by increasing the tubular glucose load and the expression of SGLT2 (as shown in mice), which maintains hyperglycaemia. Inhibitors of SGLT2 enhance urinary glucose excretion and thereby lower blood glucose levels in type 1 and type 2 diabetes. The load-dependent increase in SGLT1-mediated glucose reabsorption explains why SGLT2 inhibitors in normoglycaemic conditions enhance urinary glucose excretion to only ~50% of the filtered glucose. The role of SGLT1 in both renal and intestinal glucose reabsorption provides a rationale for the development of dual SGLT1/2 inhibitors. SGLT2 inhibitors lower blood glucose levels independent of insulin and induce pleiotropic actions that may be relevant in the context of lowering cardiovascular risk. Ongoing long-term clinical studies will determine whether SGLT2 inhibitors have a safety profile and exert cardiovascular benefits that are superior to traditional agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inhibitors of sodium-glucose cotransporter 2 reduce rates of hyperglycemia in patients with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion. 10”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [10]
In the citing paper
“Sodium/glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels by preventing glucose and sodium reabsorption in the proximal tubule (8–10).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Research works printed but not linked: 6
- International Diabetes Federation, 2013, IDF diabetes Atlas
- Barfuss DW, 1981, Am J Physiol, 241, F322
- Turner RJ, 1982, Am J Physiol, 242, F406
- Wells RG, 1992, Am J Physiol, 263, F459
- Petersen C., 1835, Annales Académie Science Française, 15, 178
- von Mering J., 1886, Centralbl Med Wiss, 531
Cited by
Sorted by citations
Items 201–300 of 395
Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?
Clapham, J. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9882-1_1 · Cited by 15
Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease
Escott, G. M., da Silveira, L. G., Cancelier, V. D. A., Dall’Agnol, A., & Silveiro, S. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107774 · Cited by 16
Seki, H., Kuratani, N., Shiga, T., Iwasaki, Y., Karita, K., Yasuda, K., & Yorozu, T. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049592 · Cited by 14
Moss, A. S., Dimitropoulos, G., Connolly, D. L., & Lip, G. Y. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1350647 · Cited by 15
Li, X., Wu, H., Peng, H., & Jiang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1078686 · Cited by 15
Is the proximal tubule the focus of tubulointerstitial fibrosis?
Peng, Z., Wang, H., Zheng, J., Wang, J., Xiang, Y., Liu, C., Ji, M., Liu, H., Pan, L., Qin, X., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13508 · Cited by 14
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L., Li, Y., Yuan, X., Xu, D., & Zhou, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399367 · Cited by 17
New drugs: big changes in conservative heart failure therapy?
Berliner, D., & Bauersachs, J. K. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy421 · Cited by 14
Yurista, S. R., Silljé, H. H. W., van Goor, H., Hillebrands, J., Heerspink, H. J. L., Montenegro, L. D. M., Oberdorf‐Maass, S. U., de Boer, R. A., & Westenbrink, B. D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06954-6 · Cited by 14
Kuroda, S., Kobashi, Y., Oi, T., Amada, H., Okumura-Kitajima, L., Io, F., Yamamto, K., & Kakinuma, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.035 · Cited by 14
Özçelik, S. (2019) · Northern Clinics of Istanbul · doi:10.14744/nci.2019.22697 · Cited by 14
Watada, H., Yamauchi, T., Yamamoto, F., Taniguchi, A., Yarush, L., Heilmann, C. J., & Yasui, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1782884 · Cited by 13
Wang, Y., Shao, X., & Liu, Z. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0616 · Cited by 13
Kaku, K., Yamamoto, K., Fukushima, Y., Lliev, H., & Yasui, A. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2054987 · Cited by 13
Chen, H., Yang, Y., Meng, R., & Liu, X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14297 · Cited by 13
DeFronzo, R. A., Lee, C. S., & Köhler, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0724-y · Cited by 14
Ito, D., Inoue, K., Saito, D., Hamaguchi, K., Kaneko, K., Sumita, T., Inukai, K., Inoue, I., & Shimada, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01176-x · Cited by 13
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on the ‘Forgotten’ Right Ventricle
Qu, L., Duan, X., & Chen, H. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15103 · Cited by 12
Quisi, A., Quisi, N. S. N., Alıcı, G., Donma, İ., Yıldırım, A., & Genç, Ö. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2500892 · Cited by 12
Deligiannidou, G.-E., Philippou, E., Vidaković, M., Berghe, W. V., Heraclides, A., Grdović, N., Mihailović, M., & Kontogiorgis, C. A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190705191000 · Cited by 12
The Sniffing Kidney: Roles for Renal Olfactory Receptors in Health and Disease
Shepard, B. D. (2021) · Kidney360 · doi:10.34067/kid.0000712021 · Cited by 12
Zhai, M., Du, X., Changmei, L., & Xu, H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.703937 · Cited by 12
Tian, L., Ai, S., Zheng, H., Yang, H., Zhou, M., Tang, J., Liu, W., Zhao, W., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.986186 · Cited by 12
Yadav, J., Ahsan, F., Panda, P., Mahmood, T., Ansari, V. A., & Shamim, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271026231127051545 · Cited by 11
Imai, T., Akimoto, T., Ito, C., Masuda, T., & Nagata, D. (2015) · Drug Target Insights · doi:10.4137/dti.s31710 · Cited by 12
Cardiovascular Outcome Trials with Glucose-Lowering Drugs
Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01505-3 · Cited by 11
Kubica, J., Kubica, A., Grzelakowska, K., Stolarek, W., Grąbczewska, Z., Michalski, P., Niezgoda, P., Bartuś, S., Budaj, A., Dąbrowski, M., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0133 · Cited by 14
Cesaro, A., Acerbo, V., Vetrano, E., Signore, G., Scherillo, G., Rotolo, F. P., Michele, G. D., Scialla, F., Raucci, G., Panico, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098099 · Cited by 12
Li, X., Zhang, Q., Zhou, X., Guo, S., Jiang, S., Zhang, Y., Zhang, R., Dong, J., & Liao, L. (2021) · Aging · doi:10.18632/aging.202945 · Cited by 11
Vadasz, B., Arazi, M., Shukha, Y., Koren, O., & Taher, R. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02607-2 · Cited by 10
Xu, B., Li, S., Kang, B., Fan, S., Chen, C., Li, W., Chen, J., He, Z., Tang, F., & Zhou, J. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08836-0 · Cited by 10
Pan, J., Yang, H., Lu, J., Chen, L., Wen, T., Zhao, S., & Shi, L. (2025) · Neuroendocrinology · doi:10.1159/000543533 · Cited by 10
Liu, T., Li, R., Wang, X., Gao, X., & Zhang, X. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.09.031 · Cited by 11
Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
Goldman, J. D. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13226 · Cited by 11
Gourzoulidis, G., Tzanetakos, C., Ioannidis, I., Tsimihodimos, V., Diogo, V., Karpouzos, G., Papageorgiou, G., & Kourlaba, G. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01013-w · Cited by 10
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Prandi, F. R., Barone, L., Lecis, D., Belli, M., Sergi, D., Milite, M., Lerakis, S., Romeo, F., & Barillà, F. (2022) · Biomolecules · doi:10.3390/biom12101349 · Cited by 12
Effects of empagliflozin on reproductive system in men without diabetes
Kosinski, C., Papadakis, G. E., Salamin, O., Kuuranne, T., Nicoli, R., Pitteloud, N., & Zanchi, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-64684-3 · Cited by 9
Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors
Mederle, A. L., Dumitrescu, P., Borza, C., & Kundnani, N. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010188 · Cited by 9
SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes
Cheng, T.-H., Lin, K.-C., Chuang, A. T.-M., Cheng, M. C., Shao, S., Lin, S. J., Lin, T.-Y., Tsai, Y.-S., Lai, E. C., Hu, C., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.34485 · Cited by 9
Alkas, J., Bosi, A., Sjölander, A., Barany, P. F., Elinder, C., Fu, E. L., & Carrero, J. J. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01505-8 · Cited by 9
Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023) · Endocrines · doi:10.3390/endocrines4030045 · Cited by 14
Naito, A., Nagatomo, Y., Kawai, A., Iwashita, M., Nakazawa, R., Taruoka, A., Takefuji, A., Yasuda, R., Toya, T., Ikegami, Y., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020141 · Cited by 10
Eroglu, T. E., Coronel, R., & Souverein, P. C. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae022 · Cited by 9
Ito, D., Inoue, K., Sumita, T., Hamaguchi, K., Kaneko, K., Yanagisawa, M., Inukai, K., Inoue, I., Noda, M., & Shimada, A. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3491w · Cited by 9
Ohashi, N., Aoki, T., Matsuyama, T., Ishigaki, S., Isobe, S., Fujikura, T., Hashimoto, T., Tsuriya, D., Morita, H., Kato, A., et al. (2020) · Medical Science Monitor · doi:10.12659/msm.926086 · Cited by 9
Wright, E. M., Sala‐Rabanal, M., Ghezzi, C., & Loo, D. D. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00046-3 · Cited by 11
Self-citationSGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
KUMAR, K. M. P., Unnikrishnan, A., Jariwala, P. V., Mehta, A., Chaturvedi, R., Panchal, S., Lakhani, P., Acharya, R., & Dixit, J. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_377_23 · Cited by 10
Kaku, K., Yamamoto, K., Fukushima, Y., Mizuno, S., & Nitta, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2062322 · Cited by 8
Zaghloul, N., Awaisu, A., Mahfouz, A., Alyafei, S., & Elewa, H. F. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01464-x · Cited by 9
Le, Y., Yang, J., Li, F., Jiang, Y., Wei, T., Wang, D., Wang, K., Cui, X., Lin, X., Yang, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3607 · Cited by 8
Tsukamoto, S., Kobayashi, K., Toyoda, M., Hatori, N., Kanaoka, T., Wakui, H., Sakai, H., Furuki, T., Chin, K., Ito, S., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01464-y · Cited by 8
SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
Bertinat, R., Nualart, F., & Yáñez, A. J. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25286 · Cited by 8
Sodium–Glucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays Diagnosis
Leslie, B. R., Gerwin, L. E., & Taylor, S. I. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1463 · Cited by 8
Iwamoto, M., Kubota, T., Sakurai, Y., Wada, N., Shioda, S., Yamauchi, T., Kadowaki, T., & Kubota, N. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.971 · Cited by 6
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes
Gallwitz, B. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1382471 · Cited by 7
Abdel‐Hamid, A. A. M., & Firgany, A. E. L. (2019) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2019.05.002 · Cited by 7
Chan, Y., Hsu, T., Wang, C., Kao, Y., Huang, C., & Chu, P. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12877 · Cited by 7
Chen, L., Liu, Q., Li, X., Zhang, L., Dong, W., Li, Q., Su, H., Luo, G., Huang, Y., & Yang, X. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177320 · Cited by 6
A review of cardiovascular benefits of SGLT2 inhibitors
Zhang, Y., & Han, Q. (2022) · Medicine · doi:10.1097/md.0000000000030310 · Cited by 8
Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model
Târtea, G. C., Popa‐Wagner, A., Sfredel, V., Mitran, S. I., Dan, A. O., Țucă, A.-M., Preda, A. N., Raicea, V. C., Țieranu, E. N., Cozma, D. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042118 · Cited by 6
Wan, J., Xu, F., Zuo, H., Jiang, X., Wang, Y., Jiang, Y., Chen, C., Yin, C., Cheng, J., & Li, H. (2024) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484241301191 · Cited by 6
Kishimoto, M., Yamaoki, K., & Adachi, M. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/9415347 · Cited by 6
Dapagliflozin Ameliorates Glycemic State, Lipid Profile and Renal Functions in Type 2 Diabetic Rats
Saleh, S. A., Mansour, M., Hazzaa, S. M., Younis, A., & Agamy, D. E. (2020) · Benha Medical Journal · doi:10.21608/bmfj.2020.105371 · Cited by 6
Gul, W., Naem, E., Elawad, S., & Elhadd, T. A. (2021) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000246 · Cited by 6
Sugar Transport Across Epithelia
Loo, D. D. F., & Wright, E. M. (2020) · Physiology in health and disease · doi:10.1007/978-3-030-55454-5_6 · Cited by 6
Self-citationHeart failure – what’s new and what’s changed?
Callan, P., & Clark, A. L. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s37 · Cited by 6
Bioactivities and Applications of Fruit Byproducts and Their Phytochemicals: A Mini Review
Balogun, O. T., & Kang, H. W. (2024) · Food Reviews International · doi:10.1080/87559129.2024.2383429 · Cited by 9
Function Trumps Form in Two Sugar Symporters, LacY and vSGLT
Abramson, J., & Wright, E. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073572 · Cited by 5
Self-citationBartholdy, K. V., Johansen, N. D., Landler, N. E., Skaarup, K. G., Jensen, J., Bressendorff, I. O., Schou, M., Christensen, J., Feldt‐Rasmussen, B., Vaduganathan, M., et al. (2022) · Kidney360 · doi:10.34067/kid.0006982022 · Cited by 5
Boutsikos, I., Beltsios, E. T., Schmack, B., Pantazopoulos, I. N., & Chatzis, D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.12 · Cited by 5
Strojek, K., Rokicka, D., Szymborska‐Kajanek, A., & Wróbel, M. P. (2016) · Clinical Diabetology · doi:10.5603/dk.2016.0018 · Cited by 6
Gitto, M., Vrachatis, D. A., Condorelli, G., Papathanasiou, K. A., Reimers, B., Deftereos, S. G., & Stefanini, G. G. (2021) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525719666210809121016 · Cited by 5
Yaginuma, H., Banno, R., Sun, R., Taki, K., Mizoguchi, A., Kobayashi, T., Sugiyama, M., Tsunekawa, T., Onoue, T., Takagi, H., et al. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.08.010 · Cited by 6
New strategies to tackle diabetic kidney disease
Batu, D., & Cooper, M. E. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000234 · Cited by 4
Jiménez, D. L., Gómez‐Huelgas, R., & Miramontes‐González, J. P. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1068 · Cited by 5
New Diabetes Medications Raise New Perioperative Concerns for the Anesthesiologist
DeCou, J. A., & Sams, S. H. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002740 · Cited by 5
Hushmandi, K., Salarizadeh, N., Einollahi, B., Izadi, M., Doosti, P., Behzadnia, M. J., Cho, W. C., Yousefi, T., Khoshnazar, S. M., Alimohammadi, M., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01824-0 · Cited by 4
Kang, E. H. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00986-3 · Cited by 6
Kaku, K., Nakayama, Y., Yabuuchi, J., Naito, Y., & Kanasaki, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2213477 · Cited by 4
Pathan, M. F., Akter, N., Selim, S., Amin, M. F., Afsana, F., Saifuddin, M., Kamrul-Hasan, A. B. M., Mustari, M., Chakraborty, A. K., & Hossain, R. M. M. (2024) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_29_23 · Cited by 5
Soares, R. R., Viggiani, L. F., Filho, J. M. R., & Joviano‐Santos, J. V. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111229 · Cited by 5
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
Mkrtumyan, A. M., Маркова, Т. Н., & Mishchenko, N. K. (2021) · Diabetes Mellitus · doi:10.14341/dm12541 · Cited by 4
Chen, H., Meng, R., Yang, Y., & Yu, T.-H. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2182290 · Cited by 4
Wu, Z., He, X., Xia, S., Xiao, X., Chen, J., & Li, L. (2023) · Cardiology Plus · doi:10.1097/cp9.0000000000000065 · Cited by 4
Head-to-Head in Heart Failure: Comparative Insights on Empagliflozin and Dapagliflozin
Cozma, D. C., Văcărescu, C., & Stoicescu, C. I. (2025) · Biomedicines · doi:10.3390/biomedicines13102422 · Cited by 3
Effect of SGLT2 Inhibitors on Atrial Electromechanical Delay in Patients with Type 2 Diabetes
Erzurum, M., Felekoğlu, M. A., Algül, N. I. E., Taş, A., Özbeyaz, N. B., Algül, E., Aydınyılmaz, F., Kalkan, K., & Efe, T. H. (2026) · Angiology · doi:10.1177/00033197261427837 · Cited by 4
Maruhashi, T., Tanaka, A., Takahashi, K., Higashi, Y., Node, K., & the PROCEED trial investigators (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15481 · Cited by 3
The latest emerging drugs for the treatment of diabetic cardiomyopathy
Li, M., Liu, L., Zhang, C., Deng, L., Zhong, Y., Liao, B., Li, X., Wan, Y., & Feng, J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2347468 · Cited by 3
Martha, S., Jangam, P. H., & Bhansali, S. G. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6105 · Cited by 3
Ngan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112278 · Cited by 3
Raja, M., Puntheeranurak, T., Gruber, H. J., Hinterdorfer, P., & Kinne, R. (2016) · MedChemComm · doi:10.1039/c5md00572h · Cited by 3
Kuroda, S., Kobashi, Y., Kawamura, M., Kawabe, K., Shiozawa, F., Hamada, M., Shimizu, Y., Okumura-Kitajima, L., Koretsune, H., Kimura, K., et al. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00089 · Cited by 3
Conventional and Alternative Mesenchymal Stem Cell Therapies for the Treatment of Diabetes
Rifai, L., & Saleh, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_614 · Cited by 4
Clements, J. N. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001248 · Cited by 3
Nieczyporuk, M., Tyrna, P., Cader, T., Sikora, A., & Staneta, S. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem942 · Cited by 3
Effect of Jardiance on glucose uptake into astrocytomas
Ghezzi, C., Ellingson, B. M., Lai, A., Liu, J., Barrio, J. R., & Wright, E. M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04746-8 · Cited by 3
Self-citationMultifaceted roles of Epac signaling in renal functions
Pochynyuk, O. M., Pyrshev, K. A., & Cheng, X. (2025) · Biochemical Journal · doi:10.1042/bcj20253103 · Cited by 4
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.09.021 · Cited by 3
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.01.001 · Cited by 3
Taylor, L., Asmar, O., Mandal, A., Tridente, A., Hardy, K. J., & Shokrollahi, K. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.754101 · Cited by 3
Metadata
- Authors
- Gallo, L. A., Wright, E. M., & Vallon, V.
- Affiliations
- Translational Research Institute (AU)
- University of California, Los Angeles (US)
- University of California San Diego (US)
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2015-01-23
- Volume
- 12
- Issue
- 2
- Pages
- 78-89
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- PMC
- PMC5886707
- OpenAlex
- W2142065502
- Cited by
- 395
- References
- 92
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 45 · 2023: 33 · 2022: 45 · 2021: 60 · 2020: 47 · 2019: 30 · 2018: 36 · 2017: 20 · 2016: 19 · 2015: 16
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes and Vascular Disease Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL094728)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK19567, R01 DK-56248, R01DK019567, P30DK079337, R01DK056248)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 1 diabetes, type 2 diabetes, renal glucose reabsorption, proximal tubule, SGLT1, urinary glucose excretion, hyperglycemia, cardiovascular risk, drug safety, insulin-independent glucose lowering
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Kidney Tubules, Proximal, Treatment Outcome, Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2, Molecular Targeted Therapy, Renal Reabsorption, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
